Core Viewpoint - The recent adjustment of the National Basic Medical Insurance Directory has led to a significant increase in the number of drugs covered, positively impacting A-share pharmaceutical stocks, with notable gains observed in companies like Rongke Technology and Huashi Technology [1][2]. Group 1: National Basic Medical Insurance Directory Adjustments - The total number of drugs in the basic medical insurance directory has increased to 3,253, including 1,857 Western medicines and 1,396 traditional Chinese medicines [1]. - A total of 114 new drugs have been added, with 50 classified as Class 1 innovative drugs, covering various fields such as oncology, chronic diseases, mental health, and pediatric medications [1]. - Several rare disease medications have also been included, addressing conditions like neurofibromatosis, thalassemia, hemophilia, multiple sclerosis, and growth hormone deficiency in children [1]. Group 2: Commercial Insurance Innovative Drug Directory - The first version of the commercial insurance innovative drug directory includes 19 drugs, featuring CAR-T therapies for cancer treatment and medications for rare diseases and Alzheimer's disease, complementing the basic medical insurance [1]. - Notably, Eli Lilly's tirzepatide injection, a new global "drug king," has been included for the treatment of adult type 2 diabetes, alongside similar drugs from Silver Noble Pharmaceuticals [2]. Group 3: Company Announcements and Financial Impact - As of December 8, 16 A-share listed pharmaceutical companies have reported their products being included in the national medical insurance drug directory or the commercial insurance innovative drug directory [2]. - Leading companies like Fosun Pharma, Huadong Medicine, and Heng Rui Medicine have had several products added, with Heng Rui reporting an estimated total sales of approximately 8.66 billion yuan for 2024 and 7.55 billion yuan for the first three quarters of 2025 from these newly included drugs [2]. - Innovative drugs such as JAK inhibitors for myelofibrosis and PD-1 monoclonal antibodies have also been successfully negotiated into the national medical insurance directory, enhancing their market potential [3].

Core Insights - The global biopharmaceutical innovation landscape, traditionally dominated by multinational corporations, is undergoing significant structural changes, with China's innovative drug industry emerging as a key player on the global stage [1] - China's transition from a "fast follower" to an "originator" in innovative drugs is becoming an irreversible trend, as highlighted by international media [1] - Data shows a notable increase in China's share of global clinical trials and licensing transactions, with Chinese biotech companies outperforming their U.S. counterparts in stock price growth over the past year [1][3] Group 1: Market Dynamics - Multinational corporations are increasingly inclined to source early-stage innovative pipelines from China due to cost-effectiveness, with costs in China being 30%-40% lower than in the U.S. [2] - The collaboration between domestic companies and multinationals is exemplified by the $12.5 billion upfront payment from Pfizer to 3SBio for overseas rights to a bispecific antibody, marking a record for domestic innovative drugs [2][3] - The Chinese innovative drug sector is expected to see a surge in licensing transactions, with projections indicating that total licensing amounts could exceed $100 billion in the first three quarters of 2025 [3] Group 2: Investment Trends - The biopharmaceutical sector is experiencing a business development (BD) boom, with significant transactions such as the $12 billion collaboration between Hengrui Medicine and GSK, indicating strong interest from multinational companies [3][4] - Investment institutions are focusing on the biopharmaceutical sector, with approximately 80% of the market value concentrated in biotechnology and pharmaceuticals, driving capital flow into these areas [5] - The market is witnessing a shift from "story-driven" investment decisions to a focus on the hard capabilities of companies, emphasizing the importance of clinical data and product quality [9][10] Group 3: Future Outlook - The innovative drug market is expected to thrive, with projections indicating that the Hang Seng Index could double by 2025, driven by favorable policies and a rebound in industry valuations [7] - The Chinese innovative drug sector is anticipated to recover strongly in 2025, with the overall revenue of listed companies in this sector reaching 48.83 billion yuan, a 22% year-on-year increase [7] - The market is seeing a resurgence in IPO activity, with over 20 companies currently queued for listing in Hong Kong, reflecting renewed investor interest in the biopharmaceutical sector [12][13]

Investment Rating - The report maintains a "positive" outlook on the pharmaceutical industry, particularly focusing on innovative drug sectors [3]. Core Insights - The pharmaceutical sector's performance saw a decline of 0.7% this week, while the Shanghai Composite Index rose by 0.4%. The pharmaceutical index ranked 21st among 31 sub-industries [3][4]. - The new National Medical Insurance Drug List added 114 drugs, including 50 innovative drugs, with an overall success rate of 88%, significantly up from 76% in 2024. The first commercial health insurance innovative drug list includes 19 drugs, enhancing coverage for critical areas such as cancer and chronic diseases [3][12][14]. - The establishment of the Chinese Drug Price Registration System allows companies to self-declare innovative drug prices, facilitating global pricing strategies for innovative drugs [17][18]. Market Performance - The pharmaceutical index's valuation stands at 29.3 times earnings, ranking 10th among 31 primary industries [6]. - The performance of various sub-sectors includes: raw materials (-2.5%), chemical preparations (-0.9%), and medical devices (-0.9%), while medical circulation saw an increase of 6.5% [6][4]. Recent Key Events - The report highlights significant clinical trial results from companies like Junsheng Pharmaceutical, which demonstrated advantages in glycemic control and cardiovascular benefits with its new drug HTD1801 [25]. - The report notes the strategic partnership between Kelun Pharmaceutical and Crescent for developing ADC therapies, with potential milestone payments reaching up to $1.25 billion [27][28]. - The report also mentions the IPO application of Lingke Pharmaceutical, focusing on innovative small molecule drugs for autoimmune and inflammatory diseases, with a post-investment valuation of 3.42 billion yuan [30]

Investment Rating - The report maintains a "Buy" rating for the pharmaceutical and biotechnology sector, with a focus on companies with strong R&D capabilities and commercialized innovative drug products [4][26]. Core Insights - The first commercial health insurance innovative drug directory has been released, which is expected to continuously expand the payment space for innovative drugs [2][21]. - The new basic medical insurance directory includes 127 products, with a success rate of 88% in negotiations, marking the highest success rate in nearly seven years [2][21]. - The commercial health insurance directory includes 24 drugs, with 19 successfully included, focusing on CAR-T and treatments for rare diseases and Alzheimer's [2][22]. - The report emphasizes the importance of clinical value in the pharmaceutical sector, suggesting that investments should focus on innovative drug chains and high-end medical devices [3][24]. Summary by Sections Market Review - The A-share pharmaceutical and biotechnology index fell by 1.17%, underperforming the CSI 300 index by 2.44 percentage points [1][16]. - The H-share Hang Seng Medical Health Index decreased by 0.71%, lagging behind the Hang Seng Index by 1.45 percentage points [1][16]. R&D Progress - Recent IND applications include Yifang Biotech's D-0502 and Hengrui Medicine's HRS-6257 [1][29]. - Clinical trials are ongoing for several drugs, including Shijiazhuang Pharmaceutical's SYS6002 and Zai Ding Pharmaceutical's Aigamod α [1][30]. Key Company Predictions and Valuations - The report provides earnings per share (EPS) forecasts and price-to-earnings (PE) ratios for key companies, recommending a "Buy" for companies like Innovent Biologics and WuXi AppTec [4][26]. Important Updates - The report highlights significant updates from various companies, including strategic partnerships and new product registrations [28][29]. Financial Data - Basic medical insurance revenue reached 2,108.6 billion yuan in the first nine months of 2025, with a monthly income of 227.6 billion yuan in September [33][38]. - The pharmaceutical manufacturing industry saw a revenue decline of 2.90% year-on-year for the first ten months of 2025 [47]. Policy and Market Trends - The report discusses the structural shift in domestic policies favoring innovative drugs and the impact of global economic conditions on the pharmaceutical sector [24][25].

Core Insights - The success rate of national medical insurance negotiations has reached a historical high of 88%, with 114 out of 127 drugs successfully included in the updated list, marking the highest success rate in seven years [1][2] - The updated medical insurance directory includes 114 new drugs, of which 50 are classified as innovative drugs, reflecting strong support for innovation in the pharmaceutical sector [1][2] - The total number of drugs in the national medical insurance directory has increased to 3,253, comprising 1,857 Western medicines and 1,396 traditional Chinese medicines, with the new directory set to be implemented on January 1, 2026 [1][2] Industry Outlook - The policy environment is increasingly favorable for innovative drug development, with the commercial health insurance directory expected to become a significant growth driver [1] - The international competitiveness of China's innovative drug pipeline is improving, with ongoing upgrades in export models and technological advancements driving rapid industry growth [1] - Companies such as Heng Rui Medicine (600276.SH), BeiGene (688235.SH), and Rongchang Biologics (688331.SH) are viewed positively due to the supportive policies for innovative drugs and their potential for growth in both domestic and international markets [1]

Investment Rating - The report maintains a positive outlook on the innovative drug sector and recommends focusing on companies with strong performance in medical devices, CXO, and upstream sectors [3][4]. Core Insights - The report highlights a 0.7% decline in the Shenwan Pharmaceutical Bio Index, while the Shanghai Composite Index rose by 0.4% during the same period [3][4]. - The new National Medical Insurance Drug List added 114 drugs, including 50 innovative drugs, with an overall success rate of 88%, significantly up from 76% in 2024 [3][13]. - The launch of the Chinese Drug Price Registration System allows companies to self-declare innovative drug prices, enhancing the global pricing strategy for these drugs [19][21]. - Recent clinical trial successes and milestone payments indicate a robust pipeline for several companies, including a $250 million milestone payment received by BaiLi Tianheng [26][29]. Market Performance - The Shenwan Pharmaceutical Bio Index ranked 21st among 31 Shenwan first-level sub-industries, with a current overall valuation of 29.3 times earnings, placing it 10th among all first-level industries [3][4][6]. - Various sub-sectors showed mixed performance, with medical circulation and offline pharmacies seeing increases of 6.5% and 1.8%, respectively, while raw materials and chemical preparations declined by 2.5% and 0.9% [3][6]. Recent Key Events - The report notes the release of the first Commercial Health Insurance Innovative Drug Directory, which includes 19 drugs aimed at enhancing coverage for critical diseases and rare conditions [13][18]. - The FDA's drug review center director's resignation adds uncertainty to the regulatory environment, which may impact drug approvals and market dynamics [19][21]. - The report emphasizes the importance of monitoring flu vaccine stocks and related pharmaceutical companies as flu activity rises [22]. Company Dynamics - BaiLi Tianheng received a significant milestone payment, indicating strong progress in its global drug development efforts [26]. - Junsheng Pharmaceutical announced positive results from a head-to-head clinical trial, showcasing the advantages of its new drug HTD1801 over existing treatments [29]. - Heng Rui Pharmaceutical appointed a new senior vice president from Eli Lilly, enhancing its research and development capabilities [30]. - Kelong Botai entered a strategic partnership to develop and commercialize new cancer therapies, indicating a focus on innovative treatment options [31]. IPO Dynamics - Lingke Pharmaceutical has initiated its IPO process in Hong Kong, focusing on innovative small molecule drugs for autoimmune and inflammatory diseases [34]. - Hansi Aitai's IPO application has passed the hearing process, indicating strong market interest in its dual-function antibody therapies [36].

Summary of Hengrui Medicine (600276.SS) R&D Day Takeaway Company Overview - **Company**: Hengrui Medicine (600276.SS) - **Industry**: Pharmaceuticals, specifically focusing on oncology, metabolism, and respiratory treatments Key Points Pipeline Strategy - Hengrui aims to develop **best-in-disease treatments** by leveraging its resources as a large pharmaceutical company [4] - The oncology pipeline includes: - A **one-stop solution** for breast cancer treatment covering various subgroups with drugs like HER2 TKI, HER2 ADC, CDK4/6i, SERD, and PARPi [4] - Enrollment of **95,000+ patients** in clinical trials for adjuvant therapy across six cancer indications [4] - Research on **10+ indications** for SHR-A1811 (HER2 ADC) and SHR-A2101 (Nectin-4 ADC) in phase 1 [4] - Development of **precision treatments** for pancreatic cancer targeting mutations such as KRAS and MTAP [4] Metabolism Portfolio - Hengrui is addressing obesity with a comprehensive solution that includes: - **HRS-9531** (GLP-1/GIP injection) with a filed NDA, targeting patients with BMI 35+ [4] - **HRS-9531 oral peptide** in phase 2, aiming for better tolerability [4] - **HRS-7535** (oral GLP-1 small molecule) in development as a cost-effective option [4] - **HRS-4729** (GLP-1/GIP/GCGR injection) in phase 1, focusing on weight loss and liver fat reduction [4] Respiratory Pipeline - Hengrui has established a pipeline for respiratory diseases, including: - **SHR-1905** (twice-yearly TSLP mAb) in phase 3 for type 1 and type 2 inflammation [5] - **HRS-9821** (PDE3/4i) in phase 1, offering convenient powder inhalation [5] Global Expansion Strategy - Hengrui is pursuing a **collaboration strategy** for global expansion while building its clinical operation capabilities [6] - Significant progress noted in the **NewCo Kailera** for the GLP-1 portfolio, including: - Completion of phase 1 bridging study for HRS-9531 in Australia and plans for a phase 3 global trial by the end of 2025 [6] - Establishment of a leadership team and hiring of over **150 employees** for operations [6] - Raising **US$600 million** to fund the global phase 3 trial and portfolio expansion [6] Financial Outlook - **Price Target**: Rmb76.11 with a current price of Rmb61.62, indicating an upside of **23.5%** [8] - **Market Cap**: Rmb393.1 billion / $55.6 billion [8] - **Revenue Forecast**: Expected to grow from Rmb27,984.6 million in 2024 to Rmb41,883.6 million by 2027 [8] - **Key Risks**: - Slower ramp-up of innovative drugs post NRDL listing [6] - Potential failure in key late-stage R&D programs [6] - Higher-than-expected R&D and administrative expenses for global expansion [6] - Greater-than-expected price cuts for generics and innovative drugs [6] Technological Advancements - Continuous upgrading of technology platforms, including: - Development of **RIPTAC** for addressing drug resistance [7] - Enhancements in **siRNA** and peptide platforms for better patient compliance [7] - Exploration of innovative linkers and payloads for targeted delivery [7] Conclusion Hengrui Medicine is strategically positioned in the pharmaceutical industry with a robust pipeline across oncology, metabolism, and respiratory treatments. The company's focus on global expansion through collaborations and technological advancements presents significant growth potential, albeit with inherent risks associated with R&D and market dynamics.

Group 1: National Medical Insurance Directory Inclusion - Heng Rui Medicine has multiple drugs included in the 2025 National Medical Insurance Directory [1] - Xing Qi Eye Medicine has 39 products continuing to be included in the National Medical Insurance Drug Directory [1] - Bei Da Pharmaceutical has four products included in the National Medical Insurance Drug Directory [1] - Junshi Biosciences has added indications for Tuoyi® and included Junshida® in the National Medical Insurance Directory [1] - Zhongsheng Pharmaceutical's innovative drug Angladiwei tablets have been included in the National Medical Insurance Directory through negotiation [1] - Yiling Pharmaceutical's subsidiary has its exclusive product Qifang Nasal Tablets included in the National Medical Insurance Directory, totaling 12 exclusive patented traditional Chinese medicine products [1] - Aosaikang's product Liratinib tablets (Aoyi Xin®) has been included in the 2025 National Medical Insurance Directory [1] - Kanghong Pharmaceutical's product Kangbai Xip eye injection (Langmu) has been included in the 2025 National Medical Insurance Directory [1] - Dongcheng Pharmaceutical's Technetium-99m injection has been included in the medical insurance directory; its subsidiary has received clinical trial approval for 177Lu-LNC1009 injection [1] - Micron Biomedical's Sidabena tablets have been included in the National Medical Insurance Directory for regular Class B management [1] - Haichuang Pharmaceutical's Deuteroenzalutamide soft capsules have been included in the National Medical Insurance Directory for the first time [1] - Huadong Medicine's subsidiary products and cooperative products have been included in the National Medical Insurance and commercial insurance innovative drug directory [1] - Aidi Pharmaceutical's two anti-HIV innovative drugs continue to be included in the National Medical Insurance Directory through a simplified renewal process [1] Group 2: Corporate Developments - Hengyin Technology has signed a cooperation agreement with Muxi Co., focusing on the domestic GPU scenario [1] - Jia Jian Co. is planning a change in control, with stock resuming trading on December 8 [2] - Gu Ao Technology's actual controller is planning a change in control, leading to stock suspension [2] Group 3: Financial Performance - Tianbang Food reported a commodity pig sales revenue of 654 million yuan in November, a month-on-month increase of 7.66% [3] - Tian Ci Materials' controlling shareholder has committed not to reduce company shares [3]

Summary of China Healthcare & Pharmaceuticals 3Q25 Drug Sales Tracker Industry Overview - The report focuses on the **China healthcare and pharmaceuticals industry**, specifically analyzing drug sales data for the third quarter of 2025 (3Q25) [1][2]. Key Findings - **Overall Market Performance**: The overall drug market sales in China declined by **6.2% year-on-year (y-y)** but increased by **6% quarter-on-quarter (q-q)**, totaling **CNY 226 billion** in 3Q25 [2][1]. - **Performance of Domestic Pharma Companies**: - **Hengrui**: Sales decreased by **0.1% y-y** to **CNY 5.8 billion**. - **Sinobio**: Sales fell by **0.9% y-y** to **CNY 4.1 billion**. - **Hansoh**: Sales declined by **0.8% y-y** to **CNY 2.0 billion**. - **Qilu Pharma**: Experienced a **9% y-y decline** to **CNY 4.7 billion**. - **CSPC**: Sales dropped by **17% y-y** to **CNY 3.6 billion** [4][4]. - **Biotech Companies' Growth**: - **BeOne**: Sales increased by **20.4% y-y** to **CNY 1.5 billion**. - **Innovent**: Sales rose by **24.6% y-y** to **CNY 1.5 billion**. - **Akeso**: Notable growth of **130.1% y-y** to **CNY 156 million**. - **Remegen**: Sales grew by **54.2% y-y** to **CNY 255 million** [5][5]. - **Multinational Corporations (MNCs) Performance**: - **AstraZeneca**: Sales decreased by **4.9% y-y** to **CNY 6.1 billion**. - **Novartis**: Sales fell by **7.3% y-y**. - **Roche**: Sales declined by **13.6% y-y**. - **Pfizer**: Sales dropped by **13.9% y-y** [6][6]. - **Notable Growth in Specific Products**: - **Novo Nordisk**: Sales increased by **22.3% y-y** to **CNY 3.7 billion**, driven by **Semaglutide** sales growth of **35% y-y** to **CNY 1.3 billion**. - **Eli Lilly**: Sales of **Tirzepatide** reached **CNY 2 million** in 3Q25 [7][7]. Additional Insights - **Hengrui's Specific Products**: - **Camrelizumab**: Sales rose by **34% y-y** to **CNY 445 million**. - **Pyrotinib**: Sales remained flat at **CNY 280 million**. - **Mecapegfilgrastim**: Sales increased by **4% y-y** to **CNY 435 million** [9][9]. - **Sinobio's Product Performance**: - **Anlotinib**: Sales grew by **6% y-y** to **CNY 646 million**. - **Magnesium Isoglycyrrhizinate**: Sales increased by **7% y-y** to **CNY 682 million** [9][9]. - **CSPC's Oncology Drugs**: - **Duomeisu**: Sales surged by **91% y-y** to **CNY 40 million**. - **Jinyouli**: Sales declined by **19% y-y** to **CNY 609 million** [10][10]. - **Hansoh's Oncology Drugs**: - **Almonertinib**: Sales rose by **14% y-y** to **CNY 560 million**. - **Flumatinib**: Sales increased by **25% y-y** to **CNY 185 million** [10][10]. Conclusion - The China healthcare and pharmaceuticals market is experiencing mixed results, with domestic companies facing declines while biotech firms show significant growth. MNCs are also struggling, indicating a challenging environment for the industry overall. The data suggests potential investment opportunities in biotech companies that are outperforming their peers.

Summary of Key Points from 恒瑞医药 Conference Call Company Overview - 恒瑞医药 (Hengrui Medicine) focuses on innovation and internationalization, targeting areas such as oncology, metabolism, cardiovascular, autoimmune, and degenerative diseases. The company has completed 12 licensing transactions since 2023, totaling nearly $28 billion [2][3]. Core Strategies and Innovations - The company has established and iterated platforms for cell therapy, nucleic acid drugs, gene therapy, and protein degradation agents, emphasizing innovative modules to create differentiated treatment solutions [2][6]. - In oncology, 恒瑞医药 has developed a four-pronged collaborative innovation therapy approach, including immunotherapy (PD-1, cytokines, cell therapy), targeted chemotherapy (ADC, peptide-nuclide conjugates), supportive care, and precision medicine (KRAS inhibitors) [2][9]. - In the metabolic disease sector, 恒瑞医药 has multiple oral diabetes products on the market and plans to launch a weight-loss drug, 9,531, by 2026, which has shown promising clinical efficacy and safety [2][10]. Financial and Market Performance - 恒瑞医药 has invested over 50 billion RMB in R&D, successfully launching 24 class 1 innovative drugs. The company has over 100 self-developed new drugs in clinical development and has conducted over 400 clinical trials globally [3][4]. - The sales proportion of innovative drugs increased from 34% in 2021 to 55% in the first half of 2025, with an expected growth rate of over 25% by 2027 [4][11]. Clinical Research and International Expansion - The company has made significant progress in clinical research and internationalization, including the establishment of a new R&D center in Boston and partnerships for drug development [4][20]. - 恒瑞医药 aims to expand its market presence in non-oncology fields, with a focus on cardiovascular and autoimmune diseases, and has established a biopharmaceutical division to support this growth [15][19]. Future Development Goals - 恒瑞医药 plans to launch 47 new products by 2027, with at least five new products expected to be approved by 2026. The company aims to enhance its global presence and achieve sustainable overseas financial returns [12][21]. - The company is also focused on addressing unmet clinical needs in chronic kidney disease (CKD) and has developed a comprehensive pipeline of treatments targeting various aspects of the disease [40][35]. Emerging Trends and Challenges - The prevalence of diabetes and obesity in China is rising rapidly, with significant implications for public health. 恒瑞医药 is positioned to leverage this trend by developing innovative diabetes and weight management solutions [51][56]. - The company is exploring new treatment paradigms, including combination therapies and novel drug delivery methods, to improve patient adherence and outcomes [10][57]. Conclusion - 恒瑞医药 is strategically positioned to capitalize on its innovative drug development and international expansion efforts, with a strong focus on addressing unmet medical needs across various therapeutic areas. The company's commitment to R&D and market diversification is expected to drive future growth and enhance its competitive edge in the global pharmaceutical landscape [2][12][19].